A selective inhibitor of COX-2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cimicoxib

Item No. 10006295

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]-benzenesulfonamide
CAS Number
265114-23-6
Synonyms
  • UR-8880
Molecular Formula
C16H13ClFN3O3S
Formula Weight
381.8
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: soluble
SMILES
ClC1=C(C2=CC(F)=C(OC)C=C2)N(C3=CC=C(S(N)(=O)=O)C=C3)C=N1
InChi Code
InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)
InChi Key
KYXDNECMRLFQMZ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $69

    Add

    5 mg

    $263

    Add

    10 mg

    $427

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Cimicoxib is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-2 selectively over COX-1 (IC50s = 0.005 and 3.3 μM, respectively). 1,2 It inhibits paw swelling by 93% in a rat model of adjuvant-induced arthritis when administered at a dose of 1 mg/kg.2 Cimicoxib (3 mg/kg, p.o.) inhibits carrageenan-induced decreases in paw withdrawal latency in the hot plate test in a rat model of hyperalgesia. Formulations containing cimicoxib have been used in the treatment of pain and inflammation associated with osteoarthritis or surgery in dogs.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kim, T.W., Lebkowska-Wieruszewska, B., Owen, H., et al. Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs. Vet. J. 200(1), 77-81 (2014).

    2. Almansa, C., Alfón, J., de Arriba, A.F., et al. Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. J. Med. Chem. 46, 3463-3475 (2003).